- 31.5% of product sales, or $1.7M, was recognized in Q3.
- R&D expenses rose to a healthy $14.59 million, up from $11.6 million last year.
- Cash also rose to $180.7 million, up from $156.09 million last year.
Everyone else is doing it.
Arena Pharmaceuticals (ARNA) posted a wider loss than analysts projected after today's market close.
Arena Pharmaceuticals (ARNA) stock is trading higher after receiving FDA approval for a new extended release weight-loss pill.
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate